Avigan Tablets Seek Health Canada’s Interim Order

Dr. Reddy’s Laboratories Ltd., Appili Therapeutic, and Global Response Aid FZCO announced on December 22, 2020, that Dr. Reddy’s Canada had filed an application on behalf of the consortium for REEQONUS™ (favipiravir) Tablets for the acute treatment of mild to moderate COVID-19 adult patients under Health Canada’s Interim Order Respecting the Importation, Sale, and Advertising of Drugs for Use concerning COVID-19.

REEQONUS is also known as Avigan® (favipiravir) Tablets, developed by FUJIFILM Toyama Chemical Co., Ltd.

"The filing is a testimony to our commitment of bringing a potential solution to COVID-19 for the Canadian population,” said Mitch Wilson, CEO of GRA, in a press statement.